

Review

# MicroRNAs as Mediators of Adipose Thermogenesis and Potential Therapeutic Targets for Obesity

Lunkun Ma <sup>1</sup>, Ankit Gilani <sup>2</sup>, Qian Yi <sup>3,\*</sup> and Liling Tang <sup>1,\*</sup> 

<sup>1</sup> Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China

<sup>2</sup> Weill Center for Metabolic Health, Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA

<sup>3</sup> Department of Physiology, School of Basic Medical Science, Southwest Medical University, Luzhou 646099, China

\* Correspondence: yiqian2010@yeah.net (Q.Y.); tangliling@cqu.edu.cn (L.T.)

**Simple Summary:** Thermogenesis in beige and brown adipose tissue has a significant role in combating metabolic disorders, such as type 2 diabetes and diet-induced obesity. A large number of studies in recent years have demonstrated that microRNAs play an essential role in regulating adipose thermogenesis and offer considerable potential as a critical new target for obesity treatment. In this review, we highlight the diverse roles of microRNAs in adipose thermogenesis and identify their regulatory roles in the development of obesity.

**Abstract:** Obesity is a growing health problem worldwide, associated with an increased risk of multiple chronic diseases. The thermogenic activity of brown adipose tissue (BAT) correlates with leanness in adults. Understanding the mechanisms behind BAT activation and the process of white fat “browning” has important implications for developing new treatments to combat obesity. MicroRNAs (miRNAs) are small transcriptional regulators that control gene expression in various tissues, including adipose tissue. Recent studies show that miRNAs are involved in adipogenesis and adipose tissue thermogenesis. In this review, we discuss recent advances in the role of miRNAs in adipocyte thermogenesis and obesity. The potential for miRNA-based therapies for obesity and recommendations for future research are highlighted, which may help provide new targets for treating obesity and obesity-related diseases.

**Keywords:** microRNAs; obesity; browning; adipose



**Citation:** Ma, L.; Gilani, A.; Yi, Q.; Tang, L. MicroRNAs as Mediators of Adipose Thermogenesis and Potential Therapeutic Targets for Obesity. *Biology* **2022**, *11*, 1657. <https://doi.org/10.3390/biology11111657>

Academic Editor: Xing Zeng

Received: 9 October 2022

Accepted: 11 November 2022

Published: 13 November 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Obesity is an urgent public health issue worldwide. According to World Health Assembly, in May 2022 (<https://www.worldobesity.org> (accessed on 10 September 2022)), one billion people will be obese worldwide, including one in five women and one in seven males. When the body mass index (BMI) is 30 kg/m<sup>2</sup> or higher, a person is considered obese. An increase in all-cause mortality is linked to a higher BMI, driven mainly by excess cardiovascular disease [1]. During obesity, proinflammatory M1 macrophages are increased in adipose tissue and associated with adipose tissue inflammation and insulin resistance [2]. By contrast, in lean humans and mice, relatively high numbers of anti-inflammatory M2 macrophages secrete anti-inflammatory cytokines and utilize oxidative metabolism to maintain adipose homeostasis [2]. Obesity is also associated with significant morbidity from multiple health problems, including hypertension, type 2 diabetes mellitus (T2D), cerebrovascular disease, kidney disease, and many types of cancers [3], as well as a variety of musculoskeletal illnesses [4]. As a result, obesity is highly associated with long-term physical impairments in populations worldwide. Given the health impact of obesity, it is vital to take action on obesity prevention and treatment. Traditional methods to treat

obesity include changing dietary habits and increasing physical activity. However, such weight loss is often ineffective, as fat mass loss is often only temporary, and weight regain following long-term dieting and exercise is common [5]. Bariatric surgery is considered an effective alternative for obesity. Though, metabolic bone disease caused by bariatric surgery can lead to significant and ongoing bone loss [6,7].

Aiming to better understand the occurrence and treatment of obesity has brought adipose tissue to the center of metabolic disease discussion. Adipose tissue is a metabolically active organ that plays a key role in regulating whole-body energy homeostasis [8].

Based on tissue color and unique metabolic properties, adipose tissue has been divided into two primary categories: brown adipose tissue (BAT) and white adipose tissue (WAT). WAT is essential for energy storage. The production of non-shivering heat by BAT, which utilizes energy, is necessary for maintaining body temperature [9]. Since the adult human BAT was first identified [9–11], there has been growing interest in finding obesity treatments starting with the fat itself. Converting energy-storing WAT into energy-consuming brown fat may be an effective and harmless solution to obesity. Cold exposure and  $\beta$ -adrenergic agonist treatment activate classical BAT and promote the browning of WAT. Physiological stimuli for beige adipocyte formation include cold exposure, diet, and exercise [12]. Indeed, during the last decade, cold-induced human BAT activation and recruitment have demonstrated that non-shivering thermogenesis increases energy expenditure and ultimately helps reduce body fat [13–15]. These results point to the possibility of non-shivering thermogenesis, which involves the activation and recruitment of thermogenic adipocytes to boost energy expenditure in adipose organs [16]. Brown and beige thermogenic adipocytes have more mitochondria than white adipocytes, and uncoupling protein 1 (UCP1) is substantially abundant in these mitochondria [17]. UCP1 has the function of separating substrate oxidation from adenosine triphosphate (ATP) synthesis, which creates heat. After exposure to cold, beige adipocytes are recruited in the white adipose tissue, a process known as WAT “browning” [18]. Since UCP1-promoted thermogenesis consumes a lot of energy, thermogenic adipocytes are critical for energy balance and thus promote the loss of body weight [19]. Therefore, it has become more important to look for molecular mechanisms and internal cues that control the development of thermogenic adipocytes [20]. The transcriptional regulators PR domain containing 16 (PRDM16), Peroxisome proliferator-activated receptor  $\gamma$ 2 (PPAR $\gamma$ 2), and other elements have been identified as prospective targets at the moment [21]. PRDM16 function as maintains brown adipose tissue morphology and thermogenesis [22]. PPAR $\gamma$  is a transcription factor highly expressed in adipose tissue and considered a master regulator of adipogenesis in mammals. PPAR $\gamma$  activation upregulates adiponectin and downregulates some proinflammatory gene expression [23]. PPAR $\gamma$  expression is increased in subcutaneous adipose tissue (SAT) in obese subjects, whereas its expression is decreased in obese subjects with metabolic alterations like insulin resistance [24,25]. This suggests that changes in PPAR $\gamma$  expression may function as an adaptive mechanism in the development of obesity, and other metabolic changes may influence its expression.

MicroRNAs (miRNAs) are small, highly conserved non-coding RNA molecules that play a role in gene expression regulation. Additionally, miRNAs have been identified in exosomes, which can be ingested by nearby or distant cells and then regulate recipient cells [26]. Recently, miRNAs have been recognized as regulators of adipose function by directly or indirectly regulating adipose thermogenesis. Studies have shown that the up-or down-regulation of certain specific miRNAs is the key to affecting adipose thermogenesis. miRNAs also have important regulatory roles in various other biological processes, including regulating energy and lipid metabolism in diabetes and obesity [27]. MicroRNAs are brand-new regulators of the growth and operation of adipose tissue. As a result of numerous research illuminating the function of miRNAs in adipocyte formation and metabolism, these molecules have emerged as promising therapeutic targets to address the adverse effects of adipose tissue enlargement. This review discusses miRNAs involved

in adipose tissue thermogenesis and proposes their novel therapeutic potential in the prevention and treatment of obesity.

## 2. MicroRNAs as Regulators of Adipose Thermogenesis

### 2.1. Positive Role of MicroRNAs in Adipose Thermogenesis

#### 2.1.1. miR-30b/c

MicroRNA-30 (miR-30) family is a significant component of the microRNA family. There are five members of the miR-30 family: miR-30a, miR-30b, miR-30c, miR-30d, and miR-30e. MiR-30b/c, a member of the miRNA30 family, is strongly expressed in brown fat and can promote adipogenesis, according to recent studies [28,29]. The levels of MiR-30b/c are significantly raised during brown adipocyte development [29]. It has been demonstrated that exposure to cold or stimulation of adrenergic receptors causes the production of miR-30b and miR-30c [29]. In brown adipocytes and primary subcutaneous adipocytes, overexpression of miR-30b/c significantly raises the mRNA levels of UCP1 and cell death-inducing DFFA-like effector A (Cidea), two highly expressed thermogenic makers in BAT. By contrast, suppression of miR-30 downregulates UCP1 expression in vivo and in vitro [29]. Additionally, miR-30b/c targets the 3'-UTR of the receptor-interacting protein 140 (RIP140), a corepressor of thermogenic genes, and functions as a positive regulator of thermogenesis and the browning process of WAT [29,30]. The functions of the miR-30 family in the field of adipose thermogenesis and adipose metabolism need to be revealed in future studies to provide effective targets for the treatment of obesity.

#### 2.1.2. miR-32

MicroRNA-32 (miR-32) is an androgen receptor (AR)-regulated microRNA found on chromosome 9 in intron 14 of c9orf5, the gene encoding transmembrane protein 245 (TMEM245) [31]. In both mice and humans, miR-32 is expressed in many organs, including the brain, liver, kidney, serum, and breast tissues. miR-32 is crucial to the development of many malignancies as well as several illnesses [32]. The role of miR-32 in lipid metabolism was proposed as early as 2012 [33], but its role in fat thermogenesis has only been discovered in recent years. In mice, exposure to cold causes an upregulation of miR-32, a BAT-specific super-enhancer-associated miRNA. Ng et al. [34] revealed the function of miR-32 as a regulator of thermogenesis in brown fat. Their study found that inhibition of miR-32 in vivo by injection of miR-32 antisense oligonucleotides (ASO) resulted in impaired thermogenic response and decreased core body temperature after cold exposure. The BAT of cold-exposed animals given miR-32-ASO injections did not exhibit appreciable morphological changes compared to control mice, although UCP1 expression levels markedly decreased. Fibroblast growth factor 21 (FGF21) is an endocrine molecule normally produced by the liver with multiple metabolic effects, including enhanced browning of inguinal white adipose tissue (iWAT) [35]. By blocking the tumor suppressor Tob1 and activating the p38/MAPK signaling induced by cold exposure, miR-32 directly stimulates the BAT thermogenic program and FGF21 production both in vivo and in vitro [34].

#### 2.1.3. miR-455

MicroRNA 455 (miR-455) is an RNA gene mainly associated with Pettigrew syndrome and thyroid cancer. Following treatment with bone morphogenetic protein 7 (BMP7), which has been proven to increase brown fat mass and promote brown adipocyte differentiation, miR-455 was initially identified as a crucial regulator of brown adipogenesis in multipotent mesenchymal cells [36–38]. Following in vitro and in vivo experiments, miR-455 was identified as a downstream effector of BMP7 and a genuine BAT marker for humans and rodents [34]. Furthermore, adipose-specific gain-of-function miR-455 transgenic mice display increased browning of SAT upon cold exposure compared to controls [34]. The specific regulation mechanism is that miR-455 induces the expression of PPAR $\gamma$  by targeting and inhibiting Necdin and Runx1t1, respectively. C/EBP $\beta$  later activates PPAR $\gamma$  and PGC1 $\alpha$  to recruit transcriptional complexes and other transcriptional regulators to elicit the

expression of brown fat-specific genes [36]. There are few studies on miR-455 in adipose thermogenesis, and more research is needed to clarify its potential positive role in adipose thermogenesis in the future.

#### 2.1.4. miR-203

miR-203 was originally proposed for its ability to limit the stem cell potential of skin progenitor cells and to display tumor suppressor function in various cancers [39,40]. In 2014, Kim et al. [41] identified miR-203 as a novel regulator of brown adipocyte development. In primary brown adipocytes, inhibiting miR-203 reduced the expression of brown fat indicators (such as *Ucp1*, *Pgc1*, *Cidea*, and *PPAR*) and mitochondrial markers (such as *Cox7* and *Cox8*) without changing the expression of common adipogenic markers, such as *PPAR*, *Fabp4*, and *Adiponectin* [41]. Next, new research further elucidates its important role in adipose thermogenesis. miR-203, according to Guo et al. [42], enhances glucose tolerance in high-fat diet (HFD) fed mice and encourages white adipose tissue browning in mice exposed to low temperatures. Mechanistically, miR-203 is triggered by cAMP-dependent C/EBP upregulation and suppresses IFN- signal pathway activation by directly targeting *Lyn*, a *Jak1-Stat1* activator [42]. Additionally, their research offers mechanistic insights into the regulation of inflammatory response and sub-WAT browning by the cAMP-miR-203-IFN network, which may be used to develop novel treatments for obesity and metabolic syndrome [42].

#### 2.1.5. miR-182-5p

A miRNA that is expressed in adipose tissue and is significantly more abundant in differentiated brown adipocytes than in undifferentiated cells is called miR-182-5p [43]. Additional research revealed that in both mice and humans, adipose miR-182-5p levels were inversely associated with obesity [44]. More specifically, animals exposed to cold increased the expression of miR-182-5p in adipose tissue, whereas genes involved in mitochondrial biogenesis and thermogenesis were inhibited when miR-182-5p was deficient [44]. Mechanistically, the expression of *Nr1d1* is suppressed by miR-182-5p, which then promotes the macrophage-dependent acetylcholine/PKA axis in adipocytes to encourage the browning of white adipose tissues [44]. These results demonstrate a pivotal role for miR-182-5p as a link between macrophages and adipocytes in C57BL/6 mice, which controls beige adipose thermogenesis.

#### 2.1.6. Other MicroRNAs as Positive Regulators of Adipose Thermogenesis

Several other microRNAs have important positive regulatory roles in adipose thermogenesis. For instance, the miRNA miR-337-3p is more abundant during brown adipocyte development and is strongly expressed in BAT relative to WAT [45]. The findings of Vonhögen et al. demonstrated that miR-337-3p increased adipocyte thermogenesis by blocking *Twist1*, a substance that prevents brown adipocyte mitochondrial metabolism and activity [46]. The miR17-92 cluster is substantially abundant in BAT and stimulates beige cell production in SAT to maintain core body temperature in adipocyte-specific miR17-92 cluster overexpressed C57BL/6 mice model exposed to cold [47]. The functions of miR-124-3p in adipocyte thermogenesis were discovered by Li et al. [48]. They discovered that miR-124-3p overexpression increased thermogenesis by raising the number of mitochondria in brown adipocytes.

### 2.2. Negative Role of MicroRNAs in Adipose Thermogenesis

#### 2.2.1. miR-133

miR-133 was originally found to be expressed in BAT and SAT, markedly downregulated after cold exposure, with concomitant direct targeting and negative regulation of the key thermogenesis regulator *PRDM16* [49–51]. Inhibiting miR-133 or its transcriptional regulator, myocyte enhancer factor-2 (*Mef2*), promoted brown adipocyte development and white adipocyte browning, which were associated with increased mitochondrial ac-

tivity [50]. Furthermore, mice with a double deletion of miR-133a1 and miR-133a2 result in upregulated thermogenic gene programs in SAT [52]. A reduced level of miR-133a also improves body insulin sensitivity and glucose tolerance in vivo [52]. Reversine, a synthetic purine analog, promotes the expression of brown adipocyte marker genes and increases mitochondrial content. Kim et al. [53] recently reported that ectopic production of miR-133a reversed the browning effects of Reversine.

#### 2.2.2. miR-34a

MicroRNA 34a (miR-34a) has been identified as a tumor suppressor gene in various human malignancies. Its role in adipose has begun to gain attention in recent years. Previously published studies suggested the role of miR-34a in regulating the browning of WAT [54,55]. Increased miR-34a levels in obesity have been shown by Fu et al. [55] to limit the production of beige and brown fat. miR-34a knockdown in mice with diet-induced obesity by lentivirus enhanced the production of beige fat in all types of WATs and encouraged more browning in BAT [55]. miR-34a deficiency stimulates the production of the FGF21 receptor complex (FGFR1-KL) and SIRT1, which contributes to the activation of the browning transcriptional pathway via FGF21/SIRT1-dependent deacetylation of PGC-1 [55].

#### 2.2.3. miR-27

After cold exposure, miR-27 was identified as a key upstream regulator of the transcriptional network involved in beige and brown adipogenesis [56]. miR-27 expression is downregulated in BAT and iWAT, and the knockdown of miR-27 in iWAT increases the expression of thermogenic markers *Ucp1*, *Prdm16*, and *Pgc1a* [56]. Similarly, Kong et al. [57] demonstrated that miR-27b negatively regulates WAT browning by directly targeting *Prdm16*. Their study found that the expression of brown adipocyte markers (including *Ucp1*, *Cidea*, *Cox8b*, *Cox7a1*, and *Prdm16*) was significantly reduced in the experimental group by overexpressing miR-27b in stromal vascular fraction (SVF) extracted from SAT compared with the control group. In addition, *Prdm16* and *Ucp1* protein levels were also decreased in the miR-27b overexpressed group. These results imply that miR-27b may play a significant regulatory function in regulating adipose thermogenesis.

#### 2.2.4. miR-155

miR-155 is a multifunctional miRNA abundant in immune system cells and essential for immune responses [58]. Multiple studies identified *C/EBP $\beta$* , an important pro-adipogenic transcription factor, as the target of miR-155 in many cells type, including white preadipocytes [59–61]. Chen et al. [62] clarified its role in regulating brown and beige adipocyte differentiation. In their study, the gain and loss function of miR-155 experiments indicated that miR-155 negatively regulates adipose browning [62]. In white adipocytes, miR-155 deficiency stimulates the thermogenic program. As a result, mice lacking miR-155 have a greater capacity to adjust to cold exposure and attract inducible brown/beige cells [62]. Interestingly, clinical studies have linked the expression of miR-155 to adipose tissue dysfunction and obesity, suggesting its potential role in humans [63]. Taken together, therapeutic attempts to reduce miR-155 may be a promising approach for treating obesity in humans.

#### 2.2.5. miR-327

Genome-wide miRNA profiling identified that miR-327 was significantly downregulated in stromal-vascular fraction (SVF) isolated from WAT under cold or  $\beta$ 3-adrenergic stimulation [64]. In addition, miR-327 can directly bind to the 3'-untranslated region (UTR) of *Fgf10* [64]. On the one hand, inhibition of miR-327 causes browning and boosts systemic metabolic rate in mice under thermoneutral conditions [64]. On the other hand, local miR-327 delivery to WAT by adenovirus dramatically reduces UCP1 expression and blocks cold-induced browning [64]. Collectively, this study of the role of miR-327 in adipose

thermogenesis demonstrates that microRNAs can be used to treat obesity, T2DM, and other metabolic diseases. Future miRNAs targeting Fgf10 will likely provide an effective novel approach to obesity treatment.

#### 2.2.6. miR-494-3p

It has also been observed that miR-494-3p controls white adipose thermogenesis both in vivo and in vitro. miR-494-3p levels were dramatically downregulated in the iWAT following cold exposure, as shown by Lemecha et al. [65]. Further gain and loss of function studies of miR-494-3p in 3T3-L1 adipocytes showed that overexpressed miR-494-3p inhibits adipocyte browning, mitochondrial biogenesis, and thermogenesis through PGC1- $\alpha$  [65]. There are few studies on the role of miR-494-3p in adipose function, and more research is needed to further clarify the specific role of miR-494-3p in adipose thermogenesis.

#### 2.2.7. miR-199a/214 Cluster

To screen for miRNAs important for brown adipocyte differentiation, He and colleagues found that the expression of miR-199a and miR-214 was significantly reduced during brown adipocyte differentiation by miRNA microarray analysis [43]. miR-199a/214 cluster is a negative regulator of thermogenesis by directly targeting adipose browning transcriptional regulator PRDM16 and peroxisome PGC-1 $\alpha$  [43]. According to studies, brown adipocyte differentiation is inhibited by overexpression of the miR-199a/214 cluster, suppressing the expression of thermogenic genes and mitochondrial respiration. In contrast, beige adipocytes with this cluster knocked down have higher levels of thermogenic gene expression and mitochondrial function [43].

#### 2.2.8. Other MicroRNAs as Negative Regulators of Adipose Thermogenesis


Many other microRNAs have important negative regulatory roles in adipose thermogenesis. For example, Ding et al. [66] found that mice deficient in miR-149-3p improved inguinal fat thermogenesis and elevated total body energy expenditure. Additionally, it was shown that miR-23b-5p functions as a negative regulator in the regulation of the brown adipocyte thermogenic gene program [67]. It is interesting to note that a recent study revealed lowly expressed miR-191-5p in long-term exercise-secreted extracellular vesicles enhances the browning of WAT by adversely targeting PRDM16-3'UTR, hence increasing thermogenesis and lowering obesity [68]. The function of miR-191-5p in thermogenesis also needs to be examined further in models of cold or  $\beta$ -adrenergic receptor stimuli. Finally, the negative regulatory role of microRNAs in adipose thermogenesis can also be more intuitively understood through the schematic diagram in Figure 1.

### 2.3. MicroRNAs with Controversial Functions in Adipose Thermogenesis

#### 2.3.1. miR-22

The role of miR-22 in adipocytes was proposed by Huang et al. in 2012 [69]. Their research revealed miR-22 is a crucial regulator of the equilibrium between the adipogenic and osteogenic development of mesenchymal stem cells generated from human adipose tissue [69]. The function of miR-22 in adipocyte thermogenesis is controversial. According to Diniz et al. [70], the knockout of miR-22 in C57BL/6 mice by targeting exon2 exhibits increased energy expenditure and reduced fat mass accumulation brought on by HFD compared to WT mice. Another publication from the same group using the same miR-22 KO mice model, according to Lima et al. [71], led to WAT browning and protected mice from HFD-induced mitochondrial dysfunction in WAT and BAT. In addition, compared to wild-type mice, miR-22 KO mice fed with HFD displayed increased thermogenic gene expression and adrenergic signaling in BAT [71]. However, another study by Lou et al. [72] on the thermogenic function of miR-22 showed that both global and adipocyte-specific miR-22 deficiency in mice by targeting the second exon resulted in impaired cold adaptation and suppressed thermogenic genes expression in BAT by jointly stimulating the mTORC1

and glycolytic signaling pathways. More research is needed to elucidate the exact role of miRNA22 in adipose thermogenesis.



**Figure 1.** miRNAs inhibited adipocytes browning process. Regulation of the WAT beige process involves the action of a few specific proteins and nucleic acids. This trans-acting factor orchestra regulates genes related to mitochondrial biogenesis, cellular oxidative capacity, and non-shivering thermogenesis. The action of some microRNAs (such as miR-133, miR-34a, miR-27, etc.) inhibits the process of WAT browning.

### 2.3.2. miR-33

The hypothesis that miR-33 might regulate PGC1 $\alpha$ -related brown adipocyte metabolism was raised after the gene encoding PGC1 $\alpha$ , Pparg1a, was discovered to be a miR-33 target gene in macrophages [73]. Subsequently, miR-33 was characterized by Afonso et al. [74] as a negative regulator of adaptive thermogenesis and white adipose tissue beiging. The level of miR-33 was reduced following cold exposure, and inhibiting miR-33 with miR-33 antisense oligonucleotides enhanced beige in white adipose tissue of C57BL6/J mice [74]. However, Horie et al. [75] showed that knockout of miR-33 displays impaired thermogenesis via reduced BAT activation in C57BL/6 mice. More data will be needed to further clarify the function of miR-33 in adipose thermogenesis and firmly identify how it affects adipose function.

## 3. MicroRNAs as Therapeutic Targets for Obesity

### 3.1. MicroRNAs Associated with Obesity


Obesity is a risk factor for insulin resistance and type 2 diabetes [76]. Type 2 Diabetes is inherently characterized by insulin resistance [76]. Insulin resistance (IR) is significantly influenced by elevated amounts of non-esterified fatty acids, glycerol, hormones, and pro-inflammatory cytokines produced in the adipose tissue of obese individuals [76]. Numerous clinical studies have discovered differences in miRNA expression in the adipose tissue of lean and obese individuals, suggesting that obesity may lead to altered miRNA expression

and further metabolic changes [77–83]. For instance, Meerson et al. [79] found that BMI was positively associated with miR-221 level (especially in women) and negatively associated with miR-193a-3p and miR-193b-5p levels. The differences in these microRNAs in individuals with different BMI further reveal the potential role of microRNAs in the development of obesity. In addition, the study also found that miR-378, which is overexpressed in SAT of obese individuals and mature adipocytes, can directly target adiponectin [83,84]. In contrast, another microRNA called miR-126 was reported to be repressed in SAT in obese individuals by targeting C-C Motif Chemokine Ligand 2 (CCL2) [85]. CCL2 is a chemokine secreted by adipose tissue that activates IR-related inflammatory responses [86] and is regulated by miRNAs as well [87]. It has been demonstrated that miR-130a and miR-130b, members of the miR-130 family, are reduced in the SAT of obese people and directly target PPAR $\gamma$  [83,88]. Likewise, another microRNA called miR-519 was reported to be overexpressed in SAT in morbidly obese individuals by directly targeting PPAR $\gamma$  [82].

Obesity is widely recognized to cause an increase in free fatty acids (FFA) from diet or adipose tissue lipolysis. FFA binds to TLRs such as TLR4 and TLR2, further triggering the production of numerous proinflammatory chemokines, which stimulate downstream NF- $\kappa$ B activation [86,89]. Individuals with obesity have higher levels of TLR2 and TLR4 expression in their adipose tissue, indicating that these receptors are implicated in the inflammation-related signaling associated with obesity [90]. Visceral adipose microRNA-223 is elevated in both human and mouse obesity, according to research by Deiuliis et al. [77]. The results of their experiments specifically demonstrated that the stromal vascular cells of human VAT were responsible for increasing miRNA-223 expression. By regulating TLR4 expression, miR-223 significantly impacts macrophage penetration into adipose tissue [77]. miR-1934 inhibits the expression of IL6, IL1b, and CCL2, and its expression is suppressed in the VAT of obese individuals [78]. Serum resistin levels are elevated in obese subjects, and their concentrations are directly related to IR [91]. Resistin was found to be another target of miR-1934 [78].

Several studies have found that reduced plasma levels of several members of the let-7 miRNA family are associated with obesity and T2DM [92,93]. Moreover, studies have shown that the expression of let-7a and let-7d is reduced in the SAT of obese individuals compared to lean individuals [80]. Interestingly, another study discovered that the microRNA let-7 directly targets the gene IL-6 and that overexpressing let-7 by transfecting let-7 precursors decreased IL-6 expression [94]. Taken together, obesity-induced inflammation may be mediated by reduced expression of the let-7 family of miRNAs. Similarly, another microRNA called miR-193b was also found to have reduced expression in obesity [79,80]. Obesity is associated with decreased adiponectin expression in plasma and adipose tissue, and adiponectin reduces skeletal muscle IR by promoting FFA oxidation [95–97]. Belarbi et al. [87] discovered that miR-193b expression in SAT correlated with adiponectin gene expression and insulin resistance. It is known that Interleukin 6 (IL-6) induces IR in adipose tissue [98]. It was also found that miR-193b overexpression in human subcutaneous adipocytes attenuated IL-6 secretion [80]. miR-193b regulated CCL2 production through a transcription factors network (MAX, ARNT, BHLH, and ETS1); many of those transcription factors have been identified in other inflammatory conditions [80]. Collectively, these results suggest that obesity-associated reduction in miR-193b expression leads to the development of IR by reducing adiponectin expression and increasing IL6 and CCL2 expression. The detailed mechanism diagram can also be seen in Figure 2.





**Figure 2.** Molecular pathway of miRNAs as therapeutic targets for obesity. MicroRNAs can affect obesity-related signaling pathways by regulating the activation of transcription factors and cellular proteins.

Studies have revealed a connection between obesity and the expression of two miR-221 family members, miR-221 and miR-222 [79,80,83]. According to a recent clinical investigation by Ojeda-Rodriguez et al. [83,99], obese people showed higher miR-221 expression in SAT than people of normal weight did. Obese subjects who lost significant weight after surgery had reduced miR-221 expression in SAT [100]. Surprisingly, miR-221 circulating levels were considerably lower in obese patients compared to normal-weight subjects. The study found that miR-221 was reduced in the plasma of obese children compared with normal-weight children and that weight loss resulted in increased plasma miR-221 levels [101]. Additionally, plasma miR-221 was reduced in morbidly obese subjects [102,103]. Conversely, another study found elevated serum miR-221 levels in women with metabolic syndrome compared with controls [104]. Based on this, future research needs to focus more on explaining the differences between miRNAs in adipose tissue and circulating levels of obese subjects. It has been established that obesity and T2DM are associated with reduced GLUT4 expression in SAT [105]. Shi et al. [106] demonstrated that overexpressed miR-222 in 3T3-L1 adipocytes decreased GLUT4 expression. On the one hand, studies have also demonstrated that inflammation plays a role in regulating the expression of miR-221 [100,107]. On the other hand, miR-221 is also closely related to the IR process regulated by adiponectin [79,108]. Overall, miR-221 is a particularly promising target in obesity treatment, which requires more research to reveal its specific potential application mechanism.

### 3.2. Adipokines Regulate miRNA Activity in Obesity

Adipokines are cell signaling molecules produced by adipose tissue, and they play important roles in regulating body metabolisms such as energy metabolism, inflammation, and obesity. Adipokines mainly include leptin, adiponectin, resistin, interleukin-6, and many others. Numerous studies have shown a non-negligible interaction between microRNAs and adipokines to jointly maintain metabolic homeostasis.

Several *in vivo* and *in vitro* studies have shown that leptin regulates miRNA expression in various human tissues. Animal studies have shown altered expression of many microRNAs in leptin-deficient *ob/ob* mice or T2D *db/db* mice, such as miR-184 and

miR-103 [109,110]. A clinical study also showed that in obese patients, the expression of miR-27b and miR-145 was positively correlated with the expression and activity of the leptin receptor [111]. In addition, many studies have also found that adiponectin and resistin are also involved in regulating the expression of many microRNAs in obesity-related conditions [112–115].

Many studies have found that the roles of inflammatory adipokines such as TNF $\alpha$ , IL6, and IL1 $\beta$  in obesity-related diseases are attributed to altered miRNA profiles. For example, Shi et al. [116] found that TNF $\alpha$  and IL6 induce an inflammatory response to obesity in adipose tissue by upregulating miR-146b. Similarly, some clinical studies have also confirmed the regulation of inflammatory adipokines on microRNAs. Nteeba et al. [117] found that miR-125b and miR143 levels were negatively correlated with IL1 $\beta$ , IL6, and TNF $\alpha$  mRNA levels in the ovaries of obese individuals. Moreover, increased miR-146a-5p expression was associated with elevated levels of inflammatory adipokines such as TLR4, NF $\kappa$ B, IL6, and TNF $\alpha$  in obese patients [118].

### 3.3. Influence of Obesity in the miRNome

Many omics analyses have well-revealed microRNAs associated with obesity. Herrero-Aguayo et al. [119] found that a total of 26 microRNAs were altered in the plasma of obese subjects ( $n = 4$ /body mass index  $> 30$ ) compared to controls ( $n = 4$ /body mass index  $< 25$ ) using the Affymetrix-miRNA array ( $p < 0.01$ ). Among these microRNAs, the most striking difference was miR-4454, which levels are consistently higher in obese patients and are associated with insulin resistance [119]. Additionally, Kuryłowicz et al. [120] applied next-generation sequencing (NGS) to identify visceral (VAT) and SAT samples from 47 normal-weight, obese, and obese after surgery-induced weight loss individuals with differentially expressed microRNAs (miRNAs). The results identify molecular pathways differentially regulated in the adipose tissue of normal-weight and obese subjects before and after weight loss [120]. Another omics analysis found dysregulated expression of multiple miRNAs, such as miR-200a/200b, in epididymal WAT of ob/ob mice compared to WT mice [121]. These miRNome-based analyses provide us with more obesity-related microRNA targets, which provide directions for more experimental studies on microRNA-based obesity treatment. In addition, correlative omics analysis based on measuring changes in miRNA levels during weight loss (after bariatric surgery or lifestyle intervention) is also required in the future to screen for microRNAs that can be targeted for obesity therapy.

### 3.4. Novel Approaches of MicroRNAs Delivery

Since miRNAs are involved in regulating many key factors in the development of obesity, the use of miRNAs for obesity treatment is receiving extensive attention. Regarding the delivery system of microRNAs, there are generally two main categories, viral-based miRNA delivery system, and non-viral-based miRNA delivery system.

Transgenic viruses can deliver desired oligonucleotides and anti-miRs to increase or suppress the expression of target miRNAs [122]. Viruses used in virus-based miRNA delivery systems include lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses (AAV). Currently, virus-mediated miRNA delivery has proven promising in treating many diseases. For example, Kasar et al. [123] found systemic in vivo lentiviral delivery of miR-15a/16 reduced malignancy in a mouse model of chronic lymphocytic leukemia. In addition, another study used an AAV delivery system with high transduction efficiency to overexpress miR-298 and alleviate neuromuscular disease in a mouse model [124]. These promising results illustrate the promise of using viral-based delivery systems to deliver miRNAs to treat obesity.

Although viral-based miRNA delivery systems are highly efficient, they are associated with high immunogenicity, toxicity, and size limitations. The less toxic and biocompatible non-viral-based miRNA delivery system ensures successful intracellular delivery of miRNA or miRNA expression vectors without degradation by nucleases. Non-viral-based miRNA delivery methods mainly include lipid, polymer, inorganic, and extracellular vesicle-based

methods. Lipid-based nanocarriers are currently the most widely used non-viral delivery method [125]. Multiple studies have demonstrated the successful transport of lipid complexes in vivo to treat various diseases [126–128].

With the popularity of miRNA therapy in treating various human diseases, more and more new oligonucleotide delivery strategies have emerged to improve the therapeutic effect. Argininocalix [4] arene, a novel synthetic cationic surfactant, can efficiently transfer miRNA and anti-miRNA molecules to target cells in vitro [129,130]. A compound called Neuomag<sup>®</sup> has also been shown to have a good effect on microRNA delivery [131,132]. In addition, the researchers designed a nanobody-functionalized nucleic acid nanogel for the targeted delivery of miRNAs to cells to treat tumors [133–135]. Recently, new studies have found that the use of outer membrane vesicles (OMVs) of *Escherichia coli* as a delivery system for miRNA transport in nanoscale spherical vesicles is promising in cancer therapy [136]. Moreover, using exosomes as miRNA delivery vehicles may effectively overcome miRNA degradation in vivo, which has also been shown to promote cancer cell apoptosis [137]. Collectively, these new microRNA delivery methods provide a new direction for further application in microRNA-targeted obesity treatment.

#### 4. Summary and Perspective

In this review, we highlight the diverse roles of microRNAs in adipose thermogenesis and identify their regulatory roles in the development of obesity (also refer to Table 1). In the future, we anticipate that microRNAs will be exploited to treat obesity.

**Table 1.** Summary of miRNAs involved in adipose thermogenesis.

microRNA	Cell/Tissue	Effect of Thermogenesis	Reference(s)
miR-30b/c	WAT/primary adipocytes	Positive	[29,30]
miR-32	BAT	Positive	[34]
miR-203	WAT/brown adipocytes	Positive	[41,42]
miR-337-3p	BAT/brown adipocytes	Positive	[45]
miR17-92	BAT	Positive	[47]
miR-124-3p	Brown adipocytes	Positive	[48]
miR-182-5p	WAT/primary adipocytes	Positive	[43,44]
miR-455	WAT/primary adipocytes	Positive	[36]
miR-133	BAT/WAT	Negative	[50,52,53]
miR-327	WAT	Negative	[64]
miR-149-3p	WAT	Negative	[66]
miR-199a/214	Primary adipocytes	Negative	[43]
miR-494-3p	WAT/primary adipocytes	Negative	[65]
miR-191-5p	WAT	Negative	[68]
miR-27	BAT/WAT	Negative	[56,57]
miR-155	WAT/primary adipocytes	Negative	[59–62]
miR-34a	BAT/WAT	Negative	[55]
miR-23b-5p	Brown adipocytes	Negative	[67]
miR-22	BAT/WAT/adipocytes	Controversial	[70–72]
miR-33	BAT/WAT	Controversial	[74,75]

Over the past decades, BAT has gained increasing attention as a potential target for novel therapeutic tools to combat obesity [138]. Inducible brown adipocytes (known as beige or brite adipocytes) in the WAT depot have also received more attention in recent years due to higher energy expenditure capabilities and positive effects on preventing diet-induced obesity and T2D [139]. Like other hormones or molecules, miRNAs play an important role in brown adipogenesis [140]. Significant progress has been made in understanding the physiological activities of miRNAs in adipocytes, as well as their pathological implications in obesity and accompanying metabolic problems. In vitro and in vivo studies have shown that miRNAs can positively or negatively affect brown/beige adipogenesis. At present, the role of miRNAs in adipose thermogenesis is mainly to study its regulation on

some thermogenic genes, including some marker thermogenic genes like UCP1. UCP1 is undoubtedly a significant driver of thermogenesis. Nonetheless, many studies have identified several UCP1-independent thermogenic pathways shown to be involved in the regulation of whole-body energy homeostasis [8]. For example,  $\text{Ca}^{2+}$  cycling thermogenesis and creatine cycling-related thermogenesis [141,142]. Then, in future research on microRNAs related to thermogenesis, it is also necessary to study their effects on UCP1-independent thermogenic pathways, which will enable us to have a more comprehensive and in-depth understanding of how microRNAs can be used in the targeted treatment of obesity.

Although miRNA-targeted medicines have paved the way for treating different diseases, they still face a formidable obstacle in their development. Furthermore, the application of miRNA treatment in vivo in adipose tissue is currently understudied since adipocytes are barely responsive to exogenous nucleotide transfer due to a significant number of intracellular lipid droplets [143]. Future studies may try to induce or reduce miRNA expression using viral or liposome tissue-specific delivery to further apply it to clinical therapy. Furthermore, direct microinjecting miRNAs into adipocytes may be another way to avoid these obstacles. Despite these challenges, the development of studies related to the omics identification and characterization of miRNAs associated with adipogenesis and obesity also provides new therapeutic targets.

On the other hand, because miRNAs may be carried in body fluids such as blood, they are anticipated to play an essential role in metabolic interaction between different cell types inside adipose tissue [144]. Additionally, adipose tissue is a significant source of circulating exosomal miRNAs, indicating that miRNAs are crucial for controlling gene expression in other connected tissues [144,145]. It shows that circulating miRNAs could be valuable biomarkers of brown/beige fat activity and potential treatment approaches for obesity.

Taken together, studies to date on miRNAs in adipose development suggest that while the development of miRNA-based therapies is still in its infancy, miRNAs still have potential in the field of obesity-related diseases due to well-characterized miRNA overexpression and inhibition methods, and the potency of miRNAs as genetic regulators. The presence of circulating miRNAs in patient blood creates the possibility that miRNAs may serve as exciting novel diagnostic markers related to adipogenesis and obesity. In the case of metabolic syndrome, it may also be used in conjunction with other treatments, such as anti-inflammatory therapy, to reduce obesity and its attendant complications. Despite the growing understanding of miRNA functions in adipose, further studies are needed to fully understand the complex mechanisms behind miRNA-mediated regulation of adipose thermogenesis for developing therapeutic approaches for obesity.

**Author Contributions:** Conceptualization, L.M. and A.G.; writing—original draft preparation, L.M.; writing—review and editing, A.G., Q.Y. and L.T.; supervision, L.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by The Natural Science Foundation of Chongqing (No. 2021ycjh-bgzxm0169 and No. cstc2021jcyj-cxttX0002cstc) to L.T. and Chongqing Graduate Scientific Research and Innovation Foundation of China (No. CYB19043) to L.M.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** This work was supported by a China Scholarship Council fellowship (201906050127) to L.M.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. de Gonzalez, A.B.; Hartge, P.; Cerhan, J.R.; Flint, A.J.; Hannan, L.; MacInnis, R.J.; Moore, S.C.; Tobias, G.S.; Anton-Culver, H.; Freeman, L.B.; et al. Body-Mass Index and Mortality among 1.46 Million White Adults. *N. Engl. J. Med.* **2010**, *363*, 2211–2219. [[CrossRef](#)] [[PubMed](#)]
2. Castoldi, A.; Naffah de Souza, C.; Camara, N.O.; Moraes-Vieira, P.M. The Macrophage Switch in Obesity Development. *Front. Immunol.* **2015**, *6*, 637. [[CrossRef](#)] [[PubMed](#)]
3. Lauby-Secretan, B.; Scoccianti, C.; Loomis, D.; Grosse, Y.; Bianchini, F.; Straif, K.; International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer—Viewpoint of the IARC Working Group. *N. Engl. J. Med.* **2016**, *375*, 794–798. [[CrossRef](#)]
4. Collaborators, G.B.D.O.; Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.; Moradi-Lakeh, M.; et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N. Engl. J. Med.* **2017**, *377*, 13–27. [[CrossRef](#)] [[PubMed](#)]
5. Astrup, A.; Lundsgaard, C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. *Exp. Clin. Endocr. Diabetes* **1998**, *106*, 29–34. [[CrossRef](#)] [[PubMed](#)]
6. Yu, E.W. Bone metabolism after bariatric surgery. *J. Bone Min. Res.* **2014**, *29*, 1507–1518. [[CrossRef](#)]
7. Balsa, J.A.; Botella-Carretero, J.I.; Peromingo, R.; Caballero, C.; Munoz-Malo, T.; Villafruela, J.J.; Arrieta, F.; Zamarron, I.; Vazquez, C. Chronic increase of bone turnover markers after biliopancreatic diversion is related to secondary hyperparathyroidism and weight loss. Relation with bone mineral density. *Obes. Surg.* **2010**, *20*, 468–473. [[CrossRef](#)] [[PubMed](#)]
8. Cohen, P.; Kajimura, S. The cellular and functional complexity of thermogenic fat. *Nat. Rev. Mol. Cell Biol.* **2021**, *22*, 393–409. [[CrossRef](#)]
9. Virtanen, K.A.; Lidell, M.E.; Orava, J.; Heglind, M.; Westergren, R.; Niemi, T.; Taittonen, M.; Laine, J.; Savisto, N.J.; Enerback, S.; et al. Functional brown adipose tissue in healthy adults. *N. Engl. J. Med.* **2009**, *360*, 1518–1525. [[CrossRef](#)]
10. Nedergaard, J.; Bengtsson, T.; Cannon, B. Unexpected evidence for active brown adipose tissue in adult humans. *Am. J. Physiol. Endocrinol. Metab.* **2007**, *293*, E444–E452. [[CrossRef](#)]
11. Cypess, A.M.; Lehman, S.; Williams, G.; Tal, I.; Rodman, D.; Goldfine, A.B.; Kuo, F.C.; Palmer, E.L.; Tseng, Y.H.; Doria, A.; et al. Identification and importance of brown adipose tissue in adult humans. *N. Engl. J. Med.* **2009**, *360*, 1509–1517. [[CrossRef](#)] [[PubMed](#)]
12. Kaisanlahti, A.; Glumoff, T. Browning of white fat: Agents and implications for beige adipose tissue to type 2 diabetes. *J. Physiol. Biochem.* **2019**, *75*, 1–10. [[CrossRef](#)] [[PubMed](#)]
13. Yoneshiro, T.; Aita, S.; Matsushita, M.; Kayahara, T.; Kameya, T.; Kawai, Y.; Iwanaga, T.; Saito, M. Recruited brown adipose tissue as an antiobesity agent in humans. *J. Clin. Investig.* **2013**, *123*, 3404–3408. [[CrossRef](#)]
14. Blondin, D.P.; Labbe, S.M.; Tingelstad, H.C.; Noll, C.; Kunach, M.; Phoenix, S.; Guerin, B.; Turcotte, E.E.; Carpentier, A.C.; Richard, D.; et al. Increased brown adipose tissue oxidative capacity in cold-acclimated humans. *J. Clin. Endocrinol. Metab.* **2014**, *99*, E438–E446. [[CrossRef](#)] [[PubMed](#)]
15. Lichtenbelt, W.; Kingma, B.; van der Lans, A.; Schellen, L. Cold exposure—An approach to increasing energy expenditure in humans. *Trends Endocrinol. Metab.* **2014**, *25*, 165–167. [[CrossRef](#)]
16. Nedergaard, J.; Cannon, B. The changed metabolic world with human brown adipose tissue: Therapeutic visions. *Cell Metab.* **2010**, *11*, 268–272. [[CrossRef](#)]
17. Wang, W.; Seale, P. Control of brown and beige fat development. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 691–702. [[CrossRef](#)]
18. Wu, J.; Bostrom, P.; Sparks, L.M.; Ye, L.; Choi, J.H.; Giang, A.H.; Khandekar, M.; Virtanen, K.A.; Nuutila, P.; Schaart, G.; et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell* **2012**, *150*, 366–376. [[CrossRef](#)]
19. Feldmann, H.M.; Golozoubova, V.; Cannon, B.; Nedergaard, J. UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. *Cell Metab.* **2009**, *9*, 203–209. [[CrossRef](#)]
20. Fu, J.; Li, Z.; Zhang, H.; Mao, Y.; Wang, A.; Wang, X.; Zou, Z.; Zhang, X. Molecular pathways regulating the formation of brown-like adipocytes in white adipose tissue. *Diabetes Metab. Res. Rev.* **2015**, *31*, 433–452. [[CrossRef](#)]
21. Ahfeldt, T.; Schinzel, R.T.; Lee, Y.K.; Hendrickson, D.; Kaplan, A.; Lum, D.H.; Camahort, R.; Xia, F.; Shay, J.; Rhee, E.P.; et al. Programming human pluripotent stem cells into white and brown adipocytes. *Nat. Cell Biol.* **2012**, *14*, 209–219. [[CrossRef](#)] [[PubMed](#)]
22. Harms, M.J.; Ishibashi, J.; Wang, W.; Lim, H.W.; Goyama, S.; Sato, T.; Kurokawa, M.; Won, K.J.; Seale, P. Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice. *Cell Metab.* **2014**, *19*, 593–604. [[CrossRef](#)] [[PubMed](#)]
23. Sharma, A.M.; Staels, B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue—Understanding obesity-related changes in regulation of lipid and glucose metabolism. *J. Clin. Endocrinol. Metab.* **2007**, *92*, 386–395. [[CrossRef](#)] [[PubMed](#)]
24. Kursawe, R.; Narayan, D.; Cali, A.M.; Shaw, M.; Pierpont, B.; Shulman, G.I.; Caprio, S. Downregulation of ADIPOQ and PPARgamma2 gene expression in subcutaneous adipose tissue of obese adolescents with hepatic steatosis. *Obesity* **2010**, *18*, 1911–1917. [[CrossRef](#)] [[PubMed](#)]
25. Redonnet, A.; Bonilla, S.; Noel-Suberville, C.; Pallet, V.; Dabadie, H.; Gin, H.; Higuieret, P. Relationship between peroxisome proliferator-activated receptor gamma and retinoic acid receptor alpha gene expression in obese human adipose tissue. *Int. J. Obes. Relat. Metab. Disord.* **2002**, *26*, 920–927. [[CrossRef](#)] [[PubMed](#)]

26. Zhang, J.; Li, S.; Li, L.; Li, M.; Guo, C.; Yao, J.; Mi, S. Exosome and exosomal microRNA: Trafficking, sorting, and function. *Genom. Proteom. Bioinform.* **2015**, *13*, 17–24. [[CrossRef](#)]
27. Kurylowicz, A. microRNAs in Human Adipose Tissue Physiology and Dysfunction. *Cells* **2021**, *10*, 3342. [[CrossRef](#)]
28. Zaragosi, L.E.; Wdziekonski, B.; Brigand, K.L.; Villageois, P.; Mari, B.; Waldmann, R.; Dani, C.; Barbry, P. Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. *Genome Biol.* **2011**, *12*, R64. [[CrossRef](#)]
29. Hu, F.; Wang, M.; Xiao, T.; Yin, B.; He, L.; Meng, W.; Dong, M.; Liu, F. miR-30 promotes thermogenesis and the development of beige fat by targeting RIP140. *Diabetes* **2015**, *64*, 2056–2068. [[CrossRef](#)]
30. Nautiyal, J.; Christian, M.; Parker, M.G. Distinct functions for RIP140 in development, inflammation, and metabolism. *Trends Endocrinol. Metab.* **2013**, *24*, 451–459. [[CrossRef](#)]
31. Ambs, S.; Prueitt, R.L.; Yi, M.; Hudson, R.S.; Howe, T.M.; Petrocca, F.; Wallace, T.A.; Liu, C.G.; Volinia, S.; Calin, G.A.; et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. *Cancer Res.* **2008**, *68*, 6162–6170. [[CrossRef](#)] [[PubMed](#)]
32. Zeng, Z.L.; Zhu, Q.; Zhao, Z.; Zu, X.; Liu, J. Magic and mystery of microRNA-32. *J. Cell Mol. Med.* **2021**, *25*, 8588–8601. [[CrossRef](#)] [[PubMed](#)]
33. Shin, D.; Howng, S.Y.; Ptacek, L.J.; Fu, Y.H. miR-32 and its target SLC45A3 regulate the lipid metabolism of oligodendrocytes and myelin. *Neuroscience* **2012**, *213*, 29–37. [[CrossRef](#)]
34. Ng, R.; Hussain, N.A.; Zhang, Q.; Chang, C.; Li, H.; Fu, Y.; Cao, L.; Han, W.; Stunkel, W.; Xu, F. miRNA-32 Drives Brown Fat Thermogenesis and Trans-activates Subcutaneous White Fat Browning in Mice. *Cell Rep.* **2017**, *19*, 1229–1246. [[CrossRef](#)]
35. Fisher, F.M.; Kleiner, S.; Douris, N.; Fox, E.C.; Mepani, R.J.; Verdeguer, F.; Wu, J.; Kharitonov, A.; Flier, J.S.; Maratos-Flier, E.; et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. *Genes Dev.* **2012**, *26*, 271–281. [[CrossRef](#)]
36. Zhang, H.; Guan, M.; Townsend, K.L.; Huang, T.L.; An, D.; Yan, X.; Xue, R.; Schulz, T.J.; Winnay, J.; Mori, M.; et al. MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1alpha signaling network. *EMBO Rep.* **2015**, *16*, 1378–1393. [[CrossRef](#)]
37. Tseng, Y.H.; Kokkotou, E.; Schulz, T.J.; Huang, T.L.; Winnay, J.N.; Taniguchi, C.M.; Tran, T.T.; Suzuki, R.; Espinoza, D.O.; Yamamoto, Y.; et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. *Nature* **2008**, *454*, 1000–1004. [[CrossRef](#)] [[PubMed](#)]
38. Schulz, T.J.; Huang, P.; Huang, T.L.; Xue, R.; McDougall, L.E.; Townsend, K.L.; Cypess, A.M.; Mishina, Y.; Gussoni, E.; Tseng, Y.H. Brown-fat paucity due to impaired BMP signalling induces compensatory browning of white fat. *Nature* **2013**, *495*, 379–383. [[CrossRef](#)]
39. Yi, R.; Poy, M.N.; Stoffel, M.; Fuchs, E. A skin microRNA promotes differentiation by repressing ‘stemness’. *Nature* **2008**, *452*, 225–229. [[CrossRef](#)]
40. Bueno, M.J.; Perez de Castro, I.; Gomez de Cedron, M.; Santos, J.; Calin, G.A.; Cigudosa, J.C.; Croce, C.M.; Fernandez-Piqueras, J.; Malumbres, M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. *Cancer Cell* **2008**, *13*, 496–506. [[CrossRef](#)]
41. Kim, H.J.; Cho, H.; Alexander, R.; Patterson, H.C.; Gu, M.; Lo, K.A.; Xu, D.; Goh, V.J.; Nguyen, L.N.; Chai, X.; et al. MicroRNAs are required for the feature maintenance and differentiation of brown adipocytes. *Diabetes* **2014**, *63*, 4045–4056. [[CrossRef](#)] [[PubMed](#)]
42. Guo, X.; Zhang, Z.; Zeng, T.; Lim, Y.C.; Wang, Y.; Xie, X.; Yang, S.; Huang, C.; Xu, M.; Tao, L.; et al. cAMP-MicroRNA-203-IFNgamma network regulates subcutaneous white fat browning and glucose tolerance. *Mol. Metab.* **2019**, *28*, 36–47. [[CrossRef](#)] [[PubMed](#)]
43. He, L.; Tang, M.; Xiao, T.; Liu, H.; Liu, W.; Li, G.; Zhang, F.; Xiao, Y.; Zhou, Z.; Liu, F.; et al. Obesity-Associated miR-199a/214 Cluster Inhibits Adipose Browning via PRDM16-PGC-1alpha Transcriptional Network. *Diabetes* **2018**, *67*, 2585–2600. [[CrossRef](#)]
44. Meng, W.; Xiao, T.; Liang, X.; Wen, J.; Peng, X.; Wang, J.; Zou, Y.; Liu, J.; Bialowas, C.; Luo, H.; et al. The miR-182-5p/FGF21/acetylcholine axis mediates the crosstalk between adipocytes and macrophages to promote beige fat thermogenesis. *JCI Insight* **2021**, *6*, e150249. [[CrossRef](#)]
45. Vonhogen, I.G.C.; El Azzouzi, H.; Olieslagers, S.; Vasilevich, A.; de Boer, J.; Tinahones, F.J.; da Costa Martins, P.A.; de Windt, L.J.; Murri, M. MiR-337-3p Promotes Adipocyte Browning by Inhibiting TWIST1. *Cells* **2020**, *9*, 1056. [[CrossRef](#)] [[PubMed](#)]
46. Jun, H.J.; Gettys, T.W.; Chang, J.S. Transcriptional Activity of PGC-1alpha and NT-PGC-1alpha Is Differentially Regulated by Twist-1 in Brown Fat Metabolism. *PPAR Res.* **2012**, *2012*, 320454. [[CrossRef](#)]
47. Huang, Y.; Zhang, H.; Dong, M.; Zhang, L.; Lin, J.; Ye, R.; Zhou, H.; Liu, X.; Jin, W. miR17-92 cluster drives white adipose tissue browning. *J. Mol. Endocrinol.* **2020**, *65*, 97–107. [[CrossRef](#)] [[PubMed](#)]
48. Li, Q.; Wang, L.; Liu, H.; Ren, W.; Zhang, Z.; Xia, B. Roles of miR-124-3p/Scd1 in urolithin A-induced brown adipocyte differentiation and succinate-dependent regulation of mitochondrial complex II. *Biochem. Biophys. Res. Commun.* **2022**, *606*, 174–181. [[CrossRef](#)] [[PubMed](#)]
49. Walden, T.B.; Timmons, J.A.; Keller, P.; Nedergaard, J.; Cannon, B. Distinct expression of muscle-specific microRNAs (myomirs) in brown adipocytes. *J. Cell Physiol.* **2009**, *218*, 444–449. [[CrossRef](#)]
50. Trajkovski, M.; Ahmed, K.; Esau, C.C.; Stoffel, M. MyomiR-133 regulates brown fat differentiation through Prdm16. *Nat. Cell Biol.* **2012**, *14*, 1330–1335. [[CrossRef](#)]

51. Yin, H.; Pasut, A.; Soleimani, V.D.; Bentzinger, C.F.; Antoun, G.; Thorn, S.; Seale, P.; Fernando, P.; van Ijcken, W.; Grosveld, F.; et al. MicroRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16. *Cell Metab.* **2013**, *17*, 210–224. [[CrossRef](#)]
52. Liu, W.; Bi, P.; Shan, T.; Yang, X.; Yin, H.; Wang, Y.X.; Liu, N.; Rudnicki, M.A.; Kuang, S. miR-133a regulates adipocyte browning in vivo. *PLoS Genet.* **2013**, *9*, e1003626. [[CrossRef](#)]
53. Kim, S.; Park, J.W.; Lee, M.G.; Nam, K.H.; Park, J.H.; Oh, H.; Lee, J.; Han, J.; Yi, S.A.; Han, J.W. Reversine promotes browning of white adipocytes by suppressing miR-133a. *J. Cell Physiol.* **2019**, *234*, 3800–3813. [[CrossRef](#)]
54. Fu, T.; Choi, S.E.; Kim, D.H.; Seok, S.; Suino-Powell, K.M.; Xu, H.E.; Kemper, J.K. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 16137–16142. [[CrossRef](#)] [[PubMed](#)]
55. Fu, T.; Seok, S.; Choi, S.; Huang, Z.; Suino-Powell, K.; Xu, H.E.; Kemper, B.; Kemper, J.K. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function. *Mol. Cell Biol.* **2014**, *34*, 4130–4142. [[CrossRef](#)] [[PubMed](#)]
56. Sun, L.; Trajkovski, M. MiR-27 orchestrates the transcriptional regulation of brown adipogenesis. *Metabolism* **2014**, *63*, 272–282. [[CrossRef](#)] [[PubMed](#)]
57. Kong, X.; Yu, J.; Bi, J.; Qi, H.; Di, W.; Wu, L.; Wang, L.; Zha, J.; Lv, S.; Zhang, F.; et al. Glucocorticoids transcriptionally regulate miR-27b expression promoting body fat accumulation via suppressing the browning of white adipose tissue. *Diabetes* **2015**, *64*, 393–404. [[CrossRef](#)] [[PubMed](#)]
58. Alivernini, S.; Gremese, E.; McSharry, C.; Tulusso, B.; Ferraccioli, G.; McInnes, I.B.; Kurowska-Stolarska, M. MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis. *Front. Immunol.* **2017**, *8*, 1932. [[CrossRef](#)]
59. He, M.; Xu, Z.; Ding, T.; Kuang, D.M.; Zheng, L. MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta. *Cell Mol. Immunol.* **2009**, *6*, 343–352. [[CrossRef](#)]
60. Worm, J.; Stenvang, J.; Petri, A.; Frederiksen, K.S.; Obad, S.; Elmen, J.; Hedtjarn, M.; Straarup, E.M.; Hansen, J.B.; Kauppinen, S. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. *Nucleic Acids Res.* **2009**, *37*, 5784–5792. [[CrossRef](#)]
61. Skarn, M.; Namlos, H.M.; Noordhuis, P.; Wang, M.Y.; Meza-Zepeda, L.A.; Myklebost, O. Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222. *Stem Cells Dev.* **2012**, *21*, 873–883. [[CrossRef](#)] [[PubMed](#)]
62. Chen, Y.; Siegel, F.; Kipschull, S.; Haas, B.; Frohlich, H.; Meister, G.; Pfeifer, A. miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. *Nat. Commun.* **2013**, *4*, 1769. [[CrossRef](#)] [[PubMed](#)]
63. Kloting, N.; Berthold, S.; Kovacs, P.; Schon, M.R.; Fasshauer, M.; Ruschke, K.; Stumvoll, M.; Bluher, M. MicroRNA expression in human omental and subcutaneous adipose tissue. *PLoS ONE* **2009**, *4*, e4699. [[CrossRef](#)] [[PubMed](#)]
64. Fischer, C.; Seki, T.; Lim, S.; Nakamura, M.; Andersson, P.; Yang, Y.; Honek, J.; Wang, Y.; Gao, Y.; Chen, F.; et al. A miR-327-FGF10-FGFR2-mediated autocrine signaling mechanism controls white fat browning. *Nat. Commun.* **2017**, *8*, 2079. [[CrossRef](#)] [[PubMed](#)]
65. Lemecha, M.; Morino, K.; Imamura, T.; Iwasaki, H.; Ohashi, N.; Ida, S.; Sato, D.; Sekine, O.; Ugi, S.; Maegawa, H. MiR-494-3p regulates mitochondrial biogenesis and thermogenesis through PGC1-alpha signalling in beige adipocytes. *Sci. Rep.* **2018**, *8*, 15096. [[CrossRef](#)]
66. Ding, H.; Zheng, S.; Garcia-Ruiz, D.; Hou, D.; Wei, Z.; Liao, Z.; Li, L.; Zhang, Y.; Han, X.; Zen, K.; et al. Fasting induces a subcutaneous-to-visceral fat switch mediated by microRNA-149-3p and suppression of PRDM16. *Nat. Commun.* **2016**, *7*, 11533. [[CrossRef](#)] [[PubMed](#)]
67. You, L.; Wang, Y.; Gao, Y.; Wang, X.; Cui, X.; Zhang, Y.; Pang, L.; Ji, C.; Guo, X.; Chi, X. The role of microRNA-23b-5p in regulating brown adipogenesis and thermogenic program. *Endocr. Connect.* **2020**, *9*, 457–470. [[CrossRef](#)]
68. Di, W.; Amdanee, N.; Zhang, W.; Zhou, Y. Long-term exercise-secreted extracellular vesicles promote browning of white adipocytes by suppressing miR-191a-5p. *Life Sci.* **2020**, *263*, 118464. [[CrossRef](#)]
69. Huang, S.; Wang, S.; Bian, C.; Yang, Z.; Zhou, H.; Zeng, Y.; Li, H.; Han, Q.; Zhao, R.C. Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. *Stem Cells Dev.* **2012**, *21*, 2531–2540. [[CrossRef](#)]
70. Diniz, G.P.; Huang, Z.P.; Liu, J.; Chen, J.; Ding, J.; Fonseca, R.I.; Barreto-Chaves, M.L.; Donato, J., Jr.; Hu, X.; Wang, D.Z. Loss of microRNA-22 prevents high-fat diet induced dyslipidemia and increases energy expenditure without affecting cardiac hypertrophy. *Clin. Sci.* **2017**, *131*, 2885–2900. [[CrossRef](#)]
71. Lima, V.M.; Liu, J.; Brandao, B.B.; Lino, C.A.; Balbino Silva, C.S.; Ribeiro, M.A.C.; Oliveira, T.E.; Real, C.C.; de Paula Faria, D.; Cederquist, C.; et al. miRNA-22 deletion limits white adipose expansion and activates brown fat to attenuate high-fat diet-induced fat mass accumulation. *Metabolism* **2021**, *117*, 154723. [[CrossRef](#)]
72. Lou, P.; Bi, X.; Tian, Y.; Li, G.; Kang, Q.; Lv, C.; Song, Y.; Xu, J.; Sheng, X.; Yang, X.; et al. MiR-22 modulates brown adipocyte thermogenesis by synergistically activating the glycolytic and mTORC1 signaling pathways. *Theranostics* **2021**, *11*, 3607–3623. [[CrossRef](#)] [[PubMed](#)]

73. Karunakaran, D.; Thrush, A.B.; Nguyen, M.A.; Richards, L.; Geoffrion, M.; Singaravelu, R.; Ramphos, E.; Shangari, P.; Ouimet, M.; Pezacki, J.P.; et al. Macrophage Mitochondrial Energy Status Regulates Cholesterol Efflux and Is Enhanced by Anti-miR33 in Atherosclerosis. *Circ. Res.* **2015**, *117*, 266–278. [[CrossRef](#)] [[PubMed](#)]
74. Afonso, M.S.; Verma, N.; van Solingen, C.; Cyr, Y.; Sharma, M.; Perie, L.; Corr, E.M.; Schlegel, M.; Shanley, L.C.; Peled, D.; et al. MicroRNA-33 Inhibits Adaptive Thermogenesis and Adipose Tissue Beiging. *Arterioscler. Thromb. Vasc. Biol.* **2021**, *41*, 1360–1373. [[CrossRef](#)] [[PubMed](#)]
75. Horie, T.; Nakao, T.; Miyasaka, Y.; Nishino, T.; Matsumura, S.; Nakazeki, F.; Ide, Y.; Kimura, M.; Tsuji, S.; Rodriguez, R.R.; et al. microRNA-33 maintains adaptive thermogenesis via enhanced sympathetic nerve activity. *Nat. Commun.* **2021**, *12*, 843. [[CrossRef](#)] [[PubMed](#)]
76. Wondmkun, Y.T. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. *Diabetes Metab. Syndr. Obes.* **2020**, *13*, 3611–3616. [[CrossRef](#)] [[PubMed](#)]
77. Deilulis, J.A.; Syed, R.; Duggineni, D.; Rutsky, J.; Rengasamy, P.; Zhang, J.; Huang, K.; Needleman, B.; Mikami, D.; Perry, K.; et al. Visceral Adipose MicroRNA 223 Is Upregulated in Human and Murine Obesity and Modulates the Inflammatory Phenotype of Macrophages. *PLoS ONE* **2016**, *11*, e0165962. [[CrossRef](#)]
78. Liu, L.; Li, Q.; Xiao, X.; Wu, C.; Gao, R.; Peng, C.; Li, D.; Zhang, W.; Du, T.; Wang, Y.; et al. miR-1934, downregulated in obesity, protects against low-grade inflammation in adipocytes. *Mol. Cell Endocrinol.* **2016**, *428*, 109–117. [[CrossRef](#)]
79. Meerson, A.; Traurig, M.; Ossowski, V.; Fleming, J.M.; Mullins, M.; Baier, L.J. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-alpha. *Diabetologia* **2013**, *56*, 1971–1979. [[CrossRef](#)]
80. Arner, E.; Mejhert, N.; Kulyte, A.; Balwierz, P.J.; Pachkov, M.; Cormont, M.; Lorente-Cebrian, S.; Ehrlund, A.; Laurencikienė, J.; Heden, P.; et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. *Diabetes* **2012**, *61*, 1986–1993. [[CrossRef](#)]
81. Heneghan, H.M.; Miller, N.; McAnena, O.J.; O'Brien, T.; Kerin, M.J. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. *J. Clin. Endocrinol. Metab.* **2011**, *96*, E846–E850. [[CrossRef](#)] [[PubMed](#)]
82. Martinelli, R.; Nardelli, C.; Pilone, V.; Buonomo, T.; Liguori, R.; Castano, I.; Buono, P.; Masone, S.; Persico, G.; Forestieri, P.; et al. miR-519d overexpression is associated with human obesity. *Obesity* **2010**, *18*, 2170–2176. [[CrossRef](#)] [[PubMed](#)]
83. Ortega, F.J.; Moreno-Navarrete, J.M.; Pardo, G.; Sabater, M.; Hummel, M.; Ferrer, A.; Rodriguez-Hermosa, J.I.; Ruiz, B.; Ricart, W.; Peral, B.; et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. *PLoS ONE* **2010**, *5*, e9022. [[CrossRef](#)]
84. Ishida, M.; Shimabukuro, M.; Yagi, S.; Nishimoto, S.; Kozuka, C.; Fukuda, D.; Soeki, T.; Masuzaki, H.; Tsutsui, M.; Sata, M. MicroRNA-378 regulates adiponectin expression in adipose tissue: A new plausible mechanism. *PLoS ONE* **2014**, *9*, e111537. [[CrossRef](#)]
85. Kulyte, A.; Belarbi, Y.; Lorente-Cebrian, S.; Bambace, C.; Arner, E.; Daub, C.O.; Heden, P.; Ryden, M.; Mejhert, N.; Arner, P. Additive effects of microRNAs and transcription factors on CCL2 production in human white adipose tissue. *Diabetes* **2014**, *63*, 1248–1258. [[CrossRef](#)]
86. Reilly, S.M.; Saltiel, A.R. Adapting to obesity with adipose tissue inflammation. *Nat. Rev. Endocrinol.* **2017**, *13*, 633–643. [[CrossRef](#)] [[PubMed](#)]
87. Belarbi, Y.; Mejhert, N.; Lorente-Cebrian, S.; Dahlman, I.; Arner, P.; Ryden, M.; Kulyte, A. MicroRNA-193b Controls Adiponectin Production in Human White Adipose Tissue. *J. Clin. Endocrinol. Metab.* **2015**, *100*, E1084–E1088. [[CrossRef](#)] [[PubMed](#)]
88. Lee, E.K.; Lee, M.J.; Abdelmohsen, K.; Kim, W.; Kim, M.M.; Srikantan, S.; Martindale, J.L.; Hutchison, E.R.; Kim, H.H.; Marasa, B.S.; et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. *Mol. Cell Biol.* **2011**, *31*, 626–638. [[CrossRef](#)]
89. Nguyen, M.T.; Favelyukis, S.; Nguyen, A.K.; Reichart, D.; Scott, P.A.; Jenn, A.; Liu-Bryan, R.; Glass, C.K.; Neels, J.G.; Olefsky, J.M. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. *J. Biol. Chem.* **2007**, *282*, 35279–35292. [[CrossRef](#)]
90. Vitseva, O.I.; Tanriverdi, K.; Tchkonja, T.T.; Kirkland, J.L.; McDonnell, M.E.; Apovian, C.M.; Freedman, J.; Gokce, N. Inducible Toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue. *Obesity* **2008**, *16*, 932–937. [[CrossRef](#)]
91. Sadashiv, Tiwari, S.; Paul, B.N.; Kumar, S.; Chandra, A.; Dhananjai, S.; Negi, M.P. Over expression of resistin in adipose tissue of the obese induces insulin resistance. *World J. Diabetes* **2012**, *3*, 135–141. [[CrossRef](#)] [[PubMed](#)]
92. Jones, A.; Danielson, K.M.; Benton, M.C.; Ziegler, O.; Shah, R.; Stubbs, R.S.; Das, S.; Macartney-Coxson, D. miRNA Signatures of Insulin Resistance in Obesity. *Obesity* **2017**, *25*, 1734–1744. [[CrossRef](#)]
93. Santovito, D.; De Nardis, V.; Marcantonio, P.; Mandolini, C.; Paganelli, C.; Vitale, E.; Buttitta, F.; Bucci, M.; Mezzetti, A.; Consoli, A.; et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: Effect of glycemic control. *J. Clin. Endocrinol. Metab.* **2014**, *99*, E1681–E1685. [[CrossRef](#)] [[PubMed](#)]
94. Sung, S.Y.; Liao, C.H.; Wu, H.P.; Hsiao, W.C.; Wu, I.H.; Jinpu, Yu; Lin, S.H.; Hsieh, C.L. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. *PLoS ONE* **2013**, *8*, e71637. [[CrossRef](#)] [[PubMed](#)]
95. Guenther, M.; James, R.; Marks, J.; Zhao, S.; Szabo, A.; Kidambi, S. Adiposity distribution influences circulating adiponectin levels. *Transl. Res.* **2014**, *164*, 270–277. [[CrossRef](#)]



96. Lihn, A.S.; Bruun, J.M.; He, G.; Pedersen, S.B.; Jensen, P.F.; Richelsen, B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. *Mol. Cell Endocrinol.* **2004**, *219*, 9–15. [[CrossRef](#)]
97. Yoon, M.J.; Lee, G.Y.; Chung, J.J.; Ahn, Y.H.; Hong, S.H.; Kim, J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. *Diabetes* **2006**, *55*, 2562–2570. [[CrossRef](#)]
98. Rotter, V.; Nagaev, I.; Smith, U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. *J. Biol. Chem.* **2003**, *278*, 45777–45784. [[CrossRef](#)] [[PubMed](#)]
99. Ojeda-Rodriguez, A.; Assmann, T.S.; Alonso-Pedrero, L.; Azcona-Sanjulian, M.C.; Milagro, F.I.; Marti, A. Circulating miRNAs in girls with abdominal obesity: miR-221-3p as a biomarker of response to weight loss interventions. *Pediatr. Obes.* **2022**, *17*, e12910. [[CrossRef](#)]
100. Ortega, F.J.; Moreno, M.; Mercader, J.M.; Moreno-Navarrete, J.M.; Fuentes-Batllevell, N.; Sabater, M.; Ricart, W.; Fernandez-Real, J.M. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and in their supernatants. *Clin. Epigenetics* **2015**, *7*, 49. [[CrossRef](#)]
101. Prats-Puig, A.; Ortega, F.J.; Mercader, J.M.; Moreno-Navarrete, J.M.; Moreno, M.; Bonet, N.; Ricart, W.; Lopez-Bermejo, A.; Fernandez-Real, J.M. Changes in circulating microRNAs are associated with childhood obesity. *J. Clin. Endocrinol. Metab.* **2013**, *98*, E1655–E1660. [[CrossRef](#)]
102. Ortega, F.J.; Mercader, J.M.; Catalan, V.; Moreno-Navarrete, J.M.; Pueyo, N.; Sabater, M.; Gomez-Ambrosi, J.; Anglada, R.; Fernandez-Formoso, J.A.; Ricart, W.; et al. Targeting the circulating microRNA signature of obesity. *Clin. Chem.* **2013**, *59*, 781–792. [[CrossRef](#)] [[PubMed](#)]
103. Withers, S.B.; Dewhurst, T.; Hammond, C.; Topham, C.H. MiRNAs as Novel Adipokines: Obesity-Related Circulating MiRNAs Influence Chemosensitivity in Cancer Patients. *Noncoding RNA* **2020**, *6*, 5. [[CrossRef](#)] [[PubMed](#)]
104. Wang, Y.T.; Tsai, P.C.; Liao, Y.C.; Hsu, C.Y.; Juo, S.H. Circulating microRNAs have a sex-specific association with metabolic syndrome. *J. Biomed. Sci.* **2013**, *20*, 72. [[CrossRef](#)] [[PubMed](#)]
105. Kouidhi, S.; Berrhouma, R.; Rouissi, K.; Jarboui, S.; Clerget-Froidevaux, M.S.; Seugnet, I.; Bchir, F.; Demeneix, B.; Guissouma, H.; Elgaaied, A.B. Human subcutaneous adipose tissue Glut 4 mRNA expression in obesity and type 2 diabetes. *Acta Diabetol.* **2013**, *50*, 227–232. [[CrossRef](#)]
106. Shi, Z.; Zhao, C.; Guo, X.; Ding, H.; Cui, Y.; Shen, R.; Liu, J. Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERalpha expression in estrogen-induced insulin resistance. *Endocrinology* **2014**, *155*, 1982–1990. [[CrossRef](#)]
107. Peng, J.; Zhou, Y.; Deng, Z.; Zhang, H.; Wu, Y.; Song, T.; Yang, Y.; Wei, H.; Peng, J. miR-221 negatively regulates inflammation and insulin sensitivity in white adipose tissue by repression of sirtuin-1 (SIRT1). *J. Cell Biochem.* **2018**, *119*, 6418–6428. [[CrossRef](#)]
108. Lustig, Y.; Barhod, E.; Ashwal-Fluss, R.; Gordin, R.; Shomron, N.; Baruch-Umansky, K.; Hemi, R.; Karasik, A.; Kanety, H. RNA-binding protein PTB and microRNA-221 coregulate AdipoR1 translation and adiponectin signaling. *Diabetes* **2014**, *63*, 433–445. [[CrossRef](#)]
109. Xie, H.; Lim, B.; Lodish, H.F. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. *Diabetes* **2009**, *58*, 1050–1057. [[CrossRef](#)]
110. Tattikota, S.G.; Rathjen, T.; McAnulty, S.J.; Wessels, H.H.; Akerman, I.; van de Bunt, M.; Hausser, J.; Esguerra, J.L.; Musahl, A.; Pandey, A.K.; et al. Argonaute2 mediates compensatory expansion of the pancreatic beta cell. *Cell Metab.* **2014**, *19*, 122–134. [[CrossRef](#)]
111. Viesti, A.C.R.; Salgado, W., Jr.; Pretti da Cunha Tirapelli, D.; dos Santos, J.S. The expression of LEP, LEPR, IGF1 and IL10 in obesity and the relationship with microRNAs. *PLoS ONE* **2014**, *9*, e93512. [[CrossRef](#)]
112. Tang, X.J.; Yang, M.H.; Cao, G.; Lu, J.T.; Luo, J.; Dai, L.J.; Huang, K.M.; Zhang, L.I. Protective effect of microRNA-138 against cerebral ischemia/reperfusion injury in rats. *Exp. Ther. Med.* **2016**, *11*, 1045–1050. [[CrossRef](#)]
113. Subedi, A.; Kim, M.J.; Nepal, S.; Lee, E.S.; Kim, J.A.; Sohn, D.H.; Song, K.; Lee, S.H.; Park, W.S.; Jeong, B.S.; et al. Globular adiponectin modulates expression of programmed cell death 4 and miR-21 in RAW 264.7 macrophages through the MAPK/NF-kappaB pathway. *FEBS Lett.* **2013**, *587*, 1556–1561. [[CrossRef](#)] [[PubMed](#)]
114. Shi, C.M.; Pang, L.X.; Ji, C.B.; Wang, J.Q.; Lin, N.; Chen, J.T.; Chen, L.; Yang, L.; Huang, F.Y.; Zhou, Y.H.; et al. Obesity-associated miR-148a is regulated by cytokines and adipokines via a transcriptional mechanism. *Mol. Med. Rep.* **2016**, *14*, 5707–5712. [[CrossRef](#)] [[PubMed](#)]
115. Rius, B.; Titos, E.; Moran-Salvador, E.; Lopez-Vicario, C.; Garcia-Alonso, V.; Gonzalez-Periz, A.; Arroyo, V.; Claria, J. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. *FASEB J.* **2014**, *28*, 836–848. [[CrossRef](#)] [[PubMed](#)]
116. Shi, C.; Zhu, L.; Chen, X.; Gu, N.; Chen, L.; Zhu, L.; Yang, L.; Pang, L.; Guo, X.; Ji, C.; et al. IL-6 and TNF-alpha induced obesity-related inflammatory response through transcriptional regulation of miR-146b. *J. Interferon Cytokine Res.* **2014**, *34*, 342–348. [[CrossRef](#)] [[PubMed](#)]
117. Nteeba, J.; Ortinau, L.C.; Perfield, J.W.; Keating, A.F. Diet-Induced Obesity Alters Immune Cell Infiltration and Expression of Inflammatory Cytokine Genes in Mouse Ovarian and Peri-Ovarian Adipose Depot Tissues. *Mol. Reprod. Dev.* **2013**, *80*, 948–958. [[CrossRef](#)]

118. Russo, A.; Bartolini, D.; Mensa, E.; Torquato, P.; Albertini, M.C.; Olivieri, F.; Testa, R.; Rossi, S.; Piroddi, M.; Cruciani, G.; et al. Physical Activity Modulates the Overexpression of the Inflammatory miR-146a-5p in Obese Patients. *IUBMB Life* **2018**, *70*, 1012–1022. [[CrossRef](#)]
119. Herrero-Aguayo, V.; Jimenez-Vacas, J.M.; Saez-Martinez, P.; Gomez-Gomez, E.; Lopez-Canovas, J.L.; Garrido-Sanchez, L.; Herrera-Martinez, A.D.; Garcia-Bermejo, L.; Macias-Gonzalez, M.; Lopez-Miranda, J.; et al. Influence of Obesity in the miRNome: miR-4454, a Key Regulator of Insulin Response Via Splicing Modulation in Prostate. *J. Clin. Endocrinol. Metab.* **2021**, *106*, e469–e484. [[CrossRef](#)] [[PubMed](#)]
120. Kurylowicz, A.; Wicik, Z.; Owczar, M.; Jonas, M.I.; Kotlarek, M.; Swierniak, M.; Lisik, W.; Jonas, M.; Noszczyk, B.; Puzianowska-Kuznicka, M. NGS Reveals Molecular Pathways Affected by Obesity and Weight Loss-Related Changes in miRNA Levels in Adipose Tissue. *Int. J. Mol. Sci.* **2017**, *19*, 66. [[CrossRef](#)]
121. Oger, F.; Gheeraert, C.; Mogilenko, D.; Benomar, Y.; Molendi-Coste, O.; Bouchaert, E.; Caron, S.; Dombrowicz, D.; Pattou, F.; Duez, H.; et al. Cell-specific dysregulation of microRNA expression in obese white adipose tissue. *J. Clin. Endocrinol. Metab.* **2014**, *99*, 2821–2833. [[CrossRef](#)] [[PubMed](#)]
122. Dasgupta, I.; Chatterjee, A. Recent Advances in miRNA Delivery Systems. *Methods Protoc.* **2021**, *4*, 10. [[CrossRef](#)] [[PubMed](#)]
123. Kasar, S.; Salerno, E.; Yuan, Y.; Underbayev, C.; Vollenweider, D.; Laurindo, M.F.; Fernandes, H.; Bonci, D.; Addario, A.; Mazzella, F.; et al. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. *Genes Immun.* **2012**, *13*, 109–119. [[CrossRef](#)] [[PubMed](#)]
124. Pourshafie, N.; Lee, P.R.; Chen, K.L.; Harmison, G.G.; Bott, L.C.; Fischbeck, K.H.; Rinaldi, C. Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents. *J. Vis. Exp.* **2018**, *138*, e55724. [[CrossRef](#)] [[PubMed](#)]
125. Zhang, Y.; Wang, Z.; Gemeinhart, R.A. Progress in microRNA delivery. *J. Control. Release* **2013**, *172*, 962–974. [[CrossRef](#)] [[PubMed](#)]
126. Xu, F.; Liao, J.Z.; Xiang, G.Y.; Zhao, P.X.; Ye, F.; Zhao, Q.; He, X.X. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma. *Cancer Med.* **2017**, *6*, 651–661. [[CrossRef](#)]
127. Pecot, C.V.; Rupaimoole, R.; Yang, D.; Akbani, R.; Ivan, C.; Lu, C.; Wu, S.; Han, H.D.; Shah, M.Y.; Rodriguez-Aguayo, C.; et al. Tumour angiogenesis regulation by the miR-200 family. *Nat. Commun.* **2013**, *4*, 2427. [[CrossRef](#)]
128. Piao, L.; Zhang, M.; Datta, J.; Xie, X.; Su, T.; Li, H.; Teknos, T.N.; Pan, Q. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. *Mol. Ther.* **2012**, *20*, 1261–1269. [[CrossRef](#)]
129. Gasparello, J.; Manicardi, A.; Casnati, A.; Corradini, R.; Gambari, R.; Finotti, A.; Sansone, F. Efficient cell penetration and delivery of peptide nucleic acids by an argininocalix[4]arene. *Sci. Rep.* **2019**, *9*, 3036. [[CrossRef](#)]
130. Gasparello, J.; Lomazzi, M.; Papi, C.; D’Aversa, E.; Sansone, F.; Casnati, A.; Donofrio, G.; Gambari, R.; Finotti, A. Efficient Delivery of MicroRNA and AntimiRNA Molecules Using an Argininocalix[4]arene Macrocycle. *Mol. Ther. Nucleic Acids* **2019**, *18*, 748–763. [[CrossRef](#)]
131. Soto-Sanchez, C.; Martinez-Navarrete, G.; Humphreys, L.; Puras, G.; Zarate, J.; Pedraz, J.L.; Fernandez, E. Enduring high-efficiency in vivo transfection of neurons with non-viral magnetoparticles in the rat visual cortex for optogenetic applications. *Nanomedicine* **2015**, *11*, 835–843. [[CrossRef](#)] [[PubMed](#)]
132. Titze de Almeida, S.S.; Horst, C.H.; Soto-Sanchez, C.; Fernandez, E.; Titze de Almeida, R. Delivery of miRNA-Targeted Oligonucleotides in the Rat Striatum by Magnetofection with Neuromag<sup>®</sup>. *Molecules* **2018**, *23*, 1825. [[CrossRef](#)]
133. Zhang, Q.; Ding, F.; Liu, X.; Shen, J.; Su, Y.; Qian, J.; Zhu, X.; Zhang, C. Nanobody-guided targeted delivery of microRNA via nucleic acid nanogel to inhibit the tumor growth. *J. Control. Release* **2020**, *328*, 425–434. [[CrossRef](#)] [[PubMed](#)]
134. Qian, H.; Tay, C.Y.; Setyawati, M.I.; Chia, S.L.; Lee, D.S.; Leong, D.T. Protecting microRNAs from RNase degradation with steric DNA nanostructures. *Chem. Sci.* **2017**, *8*, 1062–1067. [[CrossRef](#)]
135. Nahar, S.; Nayak, A.K.; Ghosh, A.; Subudhi, U.; Maiti, S. Enhanced and synergistic downregulation of oncogenic miRNAs by self-assembled branched DNA. *Nanoscale* **2017**, *10*, 195–202. [[CrossRef](#)] [[PubMed](#)]
136. Cui, C.; Guo, T.; Zhang, S.; Yang, M.; Cheng, J.; Wang, J.; Kang, J.; Ma, W.; Nian, Y.; Sun, Z.; et al. Bacteria-derived outer membrane vesicles engineered with over-expressed pre-miRNA as delivery nanocarriers for cancer therapy. *Nanomedicine* **2022**, *45*, 102585. [[CrossRef](#)]
137. Fang, Z.W.; Zhang, X.Y.; Huang, H.; Wu, J. Exosome based miRNA delivery strategy for disease treatment. *Chin. Chem. Lett.* **2022**, *33*, 1693–1704. [[CrossRef](#)]
138. Ginter, E.; Simko, V. Brown fat tissue—A potential target to combat obesity. *Bratisl. Lek. Listy* **2012**, *113*, 52–56. [[CrossRef](#)]
139. Cohen, P.; Levy, J.D.; Zhang, Y.; Frontini, A.; Kolodin, D.P.; Svensson, K.J.; Lo, J.C.; Zeng, X.; Ye, L.; Khandekar, M.J.; et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. *Cell* **2014**, *156*, 304–316. [[CrossRef](#)]
140. Goody, D.; Pfeifer, A. MicroRNAs in brown and beige fat. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2019**, *1864*, 29–36. [[CrossRef](#)]
141. Tajima, K.; Ikeda, K.; Tanabe, Y.; Thomson, E.A.; Yoneshiro, T.; Oguri, Y.; Ferro, M.D.; Poon, A.S.Y.; Kajimura, S. Wireless optogenetics protects against obesity via stimulation of non-canonical fat thermogenesis. *Nat. Commun.* **2020**, *11*, 1730. [[CrossRef](#)] [[PubMed](#)]
142. Kazak, L.; Chouchani, E.T.; Jedrychowski, M.P.; Erickson, B.K.; Shinoda, K.; Cohen, P.; Vetrivelan, R.; Lu, G.Z.; Laznik-Bogoslavski, D.; Hasenfuss, S.C.; et al. A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. *Cell* **2015**, *163*, 643–655. [[CrossRef](#)] [[PubMed](#)]

143. Romanelli, S.M.; MacDougald, O.A. Viral and Nonviral Transfer of Genetic Materials to Adipose Tissues: Toward a Gold Standard Approach. *Diabetes* **2020**, *69*, 2581–2588. [[CrossRef](#)] [[PubMed](#)]
144. Chen, Y.; Buyel, J.J.; Hanssen, M.J.; Siegel, F.; Pan, R.; Naumann, J.; Schell, M.; van der Lans, A.; Schlein, C.; Froehlich, H.; et al. Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity. *Nat. Commun.* **2016**, *7*, 11420. [[CrossRef](#)] [[PubMed](#)]
145. Thomou, T.; Mori, M.A.; Dreyfuss, J.M.; Konishi, M.; Sakaguchi, M.; Wolfrum, C.; Rao, T.N.; Winnay, J.N.; Garcia-Martin, R.; Grinspoon, S.K.; et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. *Nature* **2017**, *542*, 450–455. [[CrossRef](#)]